143 related articles for article (PubMed ID: 38438296)
1. Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility.
Rubin JL; Kreindler JL
J Cyst Fibros; 2024 Mar; 23(2):368-369. PubMed ID: 38438296
[No Abstract] [Full Text] [Related]
2. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
3. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
4. Letter to the editor: Challenges and opportunities in the development of future CFTR modulator options for people with CF.
Downey DG; Taylor-Cousar J
J Cyst Fibros; 2020 Jan; 19(1):e1-e2. PubMed ID: 31672556
[No Abstract] [Full Text] [Related]
5. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the use of highly effective modulator treatment for cystic fibrosis.
Ramos KJ; Pilewski JM; Taylor-Cousar JL
J Cyst Fibros; 2021 May; 20(3):381-387. PubMed ID: 33531206
[TBL] [Abstract][Full Text] [Related]
7. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
[No Abstract] [Full Text] [Related]
8. Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation.
Gecili E; Su W; Brokamp C; Andrinopoulou ER; Iii FJL; Pestian T; Clancy JP; Solomon GM; Brewington JJ; Szczesniak RD
J Cyst Fibros; 2021 Sep; 20(5):e69-e71. PubMed ID: 33958278
[No Abstract] [Full Text] [Related]
9. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis.
Douglas JE; Civantos AM; Locke TB; Sweis AM; Hadjiliadis D; Hong G; Dorgan DJ; Kohanski MA; Palmer JN; Adappa ND
Int Forum Allergy Rhinol; 2021 Feb; 11(2):201-203. PubMed ID: 33070454
[No Abstract] [Full Text] [Related]
10. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
Hisert KB; Birket SE; Clancy JP; Downey DG; Engelhardt JF; Fajac I; Gray RD; Lachowicz-Scroggins ME; Mayer-Hamblett N; Thibodeau P; Tuggle KL; Wainwright CE; De Boeck K
Lancet Respir Med; 2023 Oct; 11(10):916-931. PubMed ID: 37699420
[TBL] [Abstract][Full Text] [Related]
11. Time for a gut check: Pancreatic sufficiency resulting from CFTR modulator use.
Megalaa R; Gopalareddy V; Champion E; Goralski JL
Pediatr Pulmonol; 2019 Aug; 54(8):E16-E18. PubMed ID: 31066218
[TBL] [Abstract][Full Text] [Related]
12. New drug treatments for cystic fibrosis.
Smyth RL
BMJ; 2020 Jan; 368():m118. PubMed ID: 31959620
[No Abstract] [Full Text] [Related]
13. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
14. Transformative therapies for rare CFTR missense alleles.
Oliver KE; Han ST; Sorscher EJ; Cutting GR
Curr Opin Pharmacol; 2017 Jun; 34():76-82. PubMed ID: 29032041
[TBL] [Abstract][Full Text] [Related]
15. Reshma Kewalramani.
Mullard A
Nat Rev Drug Discov; 2019 Nov; 18(12):896-897. PubMed ID: 31780855
[No Abstract] [Full Text] [Related]
16. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
17. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
McGarry ME; Illek B; Ly NP; Zlock L; Olshansky S; Moreno C; Finkbeiner WE; Nielson DW
Pediatr Pulmonol; 2017 Apr; 52(4):472-479. PubMed ID: 28068001
[TBL] [Abstract][Full Text] [Related]
18. Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis.
Graeber SY; Dopfer C; Naehrlich L; Gyulumyan L; Scheuermann H; Hirtz S; Wege S; Mairbäurl H; Dorda M; Hyde R; Bagheri-Hanson A; Rueckes-Nilges C; Fischer S; Mall MA; Tümmler B
Am J Respir Crit Care Med; 2018 Jun; 197(11):1433-1442. PubMed ID: 29327948
[TBL] [Abstract][Full Text] [Related]
19. Corrector combination therapies for F508del-CFTR.
Hanrahan JW; Matthes E; Carlile G; Thomas DY
Curr Opin Pharmacol; 2017 Jun; 34():105-111. PubMed ID: 29080476
[TBL] [Abstract][Full Text] [Related]
20. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
